Polyoxometallate nanoclusters have been proposed as a suitable therapy component. It will help to deliver medications precisely to the target of a pathological process, such as a cancerous tumor, without damaging to healthy cells. Delivery is usually accomplished by electrophoresis or by injection into the bloodstream. The development is explained in theAIP Conference Proceedings.
Molybdenum polyoxometalates are a form of molybdenum formed of various oxygen molecules and containing organic groups. Their uniqueity is that they can be connected to the surface of the medicine and delivered to the tumor formation. Polyoxometallates are not harmful to living cells and are not effective in controlling their function or morphology. According toMaria Ulitko, the University of California''s biology and fundamental medicine office has begun a research into molybdenum polyox
Futher scientists want to make a vector molecule to the polyoxometallate''s surface that can distinguish cancer cells and ensure the binding of the nanocluster to them, avoiding healthy ones.
They discussed how the nanocluster would interact with doxorubicin. This is a well-known anticancer medication that is capable of destroying tumor structures, but has a low selectivity. The high levels of the medication used to destroy cancer cells are toxic to the weaker body. Researchers studied how a polyoxometallate with an antibiotic inside would affect healthy and tumor cells and determined the most appropriate concentration of the medication.
The unquestionably advantageous of targeted delivery is the possibility to adjust the medication dosage. Our findings indicate that too high a concentration of doxorubicin in a polyoxometallate capsule will also result in the death of healthy cells, and the container will not be able to keep active substances from entering DNA through the nuclear and cell membranes, according to UrFU''s head.
This technique of delivery can be applied to other tumors in the future, according to researchers. At the next stage of the study, scientists will conduct preclinical experiments on laboratory animals to evaluate the therapeutic effectiveness and safety of the system. The authors note that nanocluster compounds will be capable of administering other medications, such as anti-inflammatory ones. The developed technology will help to improve the accuracy of targeted medication delivery.